Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus

Nektar Therapeutics (NKTR) incurred a loss per share of 18 cents in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 23 cents.In the year-ago quarter, the company reported an adjusted (excluding non-cash restructuring and impairment charges) loss of 18 cents.Total revenues remained flat year over year at $24.1 million. The reported figure beat the Zacks Consensus Estimate of $16 million.See the Zacks Earnings Calendar to stay ahead of market-making news. NKTR’s Q3 Results i ...